Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) on Tuesday, plunged -5.70% from the previous trading day, before settling in for the closing price of $50.73. Within the past 52 weeks, RARE’s price has moved between $34.06 and $60.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 63.06%. The company achieved an average annual earnings per share of 24.07%. With a float of $86.37 million, this company’s outstanding shares have now reached $92.34 million.
Let’s determine the extent of company efficiency that accounts for 1276 employees. In terms of profitability, gross margin is 82.86%, operating margin of -102.49%, and the pretax margin is -107.33%.
Ultragenyx Pharmaceutical Inc (RARE) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.46%, while institutional ownership is 96.58%. The most recent insider transaction that took place on Oct 10 ’24, was worth 393,853. In this transaction Chief Financial Officer of this company sold 7,465 shares at a rate of $52.76, taking the stock ownership to the 92,301 shares. Before that another transaction happened on Sep 03 ’24, when Company’s President & CEO sold 20,000 for $55.85, making the entire transaction worth $1,117,000. This insider now owns 2,223,985 shares in total.
Ultragenyx Pharmaceutical Inc (RARE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 24.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to -15.75% drop over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Ultragenyx Pharmaceutical Inc (RARE) is currently performing well based on its current performance indicators. A quick ratio of 2.65 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.46, a number that is poised to hit -1.35 in the next quarter and is forecasted to reach -5.11 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Looking closely at Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), its last 5-days average volume was 1.1 million, which is a jump from its year-to-date volume of 0.79 million. As of the previous 9 days, the stock’s Stochastic %D was 20.88%. Additionally, its Average True Range was 1.95.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 41.59%, which indicates a significant increase from 1.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.12% in the past 14 days, which was lower than the 36.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $54.79, while its 200-day Moving Average is $48.06. However, in the short run, Ultragenyx Pharmaceutical Inc’s stock first resistance to watch stands at $49.64. Second resistance stands at $51.44. The third major resistance level sits at $52.39. If the price goes on to break the first support level at $46.88, it is likely to go to the next support level at $45.93. Now, if the price goes above the second support level, the third support stands at $44.13.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
Market capitalization of the company is 4.42 billion based on 92,344K outstanding shares. Right now, sales total 434,250 K and income totals -606,640 K. The company made 139,490 K in profit during its latest quarter, and -133,520 K in sales during its previous quarter.
